
Synthetic tuftsin analog developed in Russia — anxiolytic without sedation or dependence. Peptide investigated as a non-addictive research compound vs benzodiazepine class.
Ranges cited in research literature. Not a usage recommendation. For research use only.
Selank is a synthetic heptapeptide — Thr-Lys-Pro-Arg-Pro-Gly-Pro — created at the Institute of Molecular Genetics of the Russian Academy of Sciences from tuftsin, a natural tetrapeptide (Thr-Lys-Pro-Arg) derived from immunoglobulin G that modulates macrophage activity. The Pro-Gly-Pro tail, the same one Semax carries, was added to the fragment to protect it from peptidases and prolong its action. In Russia it has been registered since 2009 as a nasal solution.
The described mechanisms are several and not mutually exclusive: it modulates expression of GABAergic-system genes and the affinity of GABA-A receptors, inhibits the enzymes that degrade enkephalins (prolonging the endogenous opioid signal), increases BDNF expression in the hippocampus and shifts the cytokine profile, IL-6 in particular. The combined effects on GABA, serotonin and enkephalins are what place it among the peptides regulating emotional state and cognition, and what distinguish it from Semax, which is more nootropic in orientation.
Clinical evidence comes from Russian trials of moderate size in generalized anxiety disorder and neurasthenia, published in local journals and without independent replication in the West; administration in those studies was intranasal. It holds no approval outside Russia and neighboring countries. The research-market convention uses the subcutaneous route, different from the clinical one. Renova distributes it for research only.
| Class | Synthetic heptapeptide, tuftsin analog with a PGP tail |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro (7 aa) · tuftsin = TKPR |
| CAS | 129954-34-3 |
| Origin | Institute of Molecular Genetics, Russian Academy of Sciences (Myasoedov group) |
| Described mechanisms | GABA-A modulation, enkephalinase inhibition, hippocampal BDNF, cytokine profile (IL-6) |
| Clinical route | Intranasal (Russian registration, 2009); the SC route is a research convention |
| Regulatory status | Registered only in Russia and CIS countries; no FDA/EMA approval |
| Stability | Short, water-soluble peptide; no cysteine or methionine (low oxidation sensitivity) |
They share the Pro-Gly-Pro tail and the same institute of origin, but the core differs: Selank derives from tuftsin (an immune peptide) and acts on GABA, enkephalins and IL-6; Semax derives from ACTH and acts on BDNF, NGF and attention. In the Russian literature Selank is associated with emotional regulation and Semax with cognition and neuroprotection.
Because the nasal route lets a small peptide reach the central nervous system while avoiding first-pass metabolism, and it is the form in which it is registered in Russia (nasal drops). The available clinical trials used that route; the research market's subcutaneous route has no clinical data.
Tuftsin is a natural tetrapeptide (Thr-Lys-Pro-Arg) released from immunoglobulin G that stimulates macrophages. Selank is that same sequence with three added amino acids (Pro-Gly-Pro) that stabilize it; it keeps part of the immunomodulatory activity and adds the nervous-system effects.
Almost none that is clinical. Preclinical studies on gene expression and neurochemistry have appeared in international journals, but the human trials are Russian, moderate in size and without independent replication. Our Semax and Selank guide reviews that literature with its limitations.
Related reading: Semax and Selank: The Russian Peptide Nootropics
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
Your cart is empty